文献速递血栓与止血

他汀类药物与静脉血栓栓塞症一级预防:系统综述与Meta分析

Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.
PubMed 文献 · Lancet Haematol · 2017-01-13

该系统综述与Meta分析纳入36项研究(13项队列研究共3 148 259名参与者,23项随机对照试验共118 464名参与者),评估他汀类药物与首次静脉血栓栓塞症的关联。观察性研究中他汀使用与未使用的静脉血栓栓塞症合并RR为0·75(95%CI 0·65-0·87;p<0·0001);随机对照试验中他汀治疗与安慰剂或无治疗的RR为0·85(0·73-0·99;p=0·038)。作者认为现有证据提示他汀使用对静脉血栓栓塞症有益,但需进一步证据验证。

要点

  • 观察性研究中他汀使用与未使用的静脉血栓栓塞症合并RR为0·75(95%CI 0·65-0·87;p<0·0001)。
  • 随机对照试验中他汀治疗与安慰剂或无治疗的静脉血栓栓塞症RR为0·85(0·73-0·99;p=0·038)。
  • 亚组分析提示瑞舒伐他汀较其他他汀对静脉血栓栓塞症的风险最低,RR为0·57(0·42-0·75;p=0·015)。

核心结论

  • 现有观察性与干预研究的证据提示他汀使用对静脉血栓栓塞症有益。
  • 在干预研究中,瑞舒伐他汀治疗较其他他汀显著降低静脉血栓栓塞症。
  • 作者指出仍需进一步证据验证这些发现。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Web of Science、Cochrane Library及文献书目手工检索,截至2016年7月18日,并纳入与研究者邮件联系所得研究,注册号PROSPERO CRD42016035622。
  • 纳入36项研究:13项队列研究共3 148 259名参与者,23项随机对照试验(他汀 vs 安慰剂或无治疗)共118 464名参与者。
  • 纳入评估成人他汀使用与静脉血栓栓塞症、深静脉血栓或肺栓塞关联的观察性队列,以及评估他汀治疗对比安慰剂或无治疗并收集静脉血栓栓塞症、深静脉血栓或肺栓塞结局的干预研究。
  • 排除将他汀与另一种他汀或降脂药比较的研究。

主要发现

  • 观察性研究中,他汀使用与未使用相比,静脉血栓栓塞症合并RR为0·75(95%CI 0·65-0·87;p<0·0001)。
  • 随机对照试验中,他汀治疗与安慰剂或无治疗相比,静脉血栓栓塞症RR为0·85(95%CI 0·73-0·99;p=0·038)。
  • 亚组分析提示他汀效应因他汀种类不同存在显著差异,瑞舒伐他汀较其他他汀对静脉血栓栓塞症的风险最低,RR为0·57(95%CI 0·42-0·75;p=0·015)。
  • 未发现他汀使用对肺栓塞有影响的证据。
  • 与未使用他汀相比,他汀使用与深静脉血栓这一特定终点的风险显著降低相关(RR 0·77,95%CI 0·69-0·86;p<0·0001)。

关键数值与推荐

  • 观察性研究中他汀使用与未使用的静脉血栓栓塞症合并RR为0·75(95%CI 0·65-0·87;p<0·0001)。
  • 随机对照试验中他汀治疗与安慰剂或无治疗的静脉血栓栓塞症RR为0·85(95%CI 0·73-0·99;p=0·038)。
  • 瑞舒伐他汀较其他他汀对静脉血栓栓塞症的RR为0·57(95%CI 0·42-0·75;p=0·015)。
  • 他汀使用与未使用相比,深静脉血栓风险RR为0·77(95%CI 0·69-0·86;p<0·0001)。

临床怎么用

  • 作者认为现有观察性与干预研究的证据提示他汀使用对静脉血栓栓塞症有益。
  • 作者指出仍需进一步证据验证这些发现。

局限性

  • 作者指出仍需进一步证据验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statins have been suggested to have a protective effect on venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain. We sought to evaluate the extent to which statins are associated with first venous thromboembolism events. METHODS: We did a systematic review and meta-analysis of observational cohort studies and randomised controlled trials (RCTs). Relevant studies that reported associations between statins and first venous thromboembolism outcomes were identified from MEDLINE, Embase, Web of Science, Cochrane Library, and a manual search of bibliographies for studies published up until July 18, 2016, and from email correspondence with investigators. Observational cohorts that assessed the association of statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults were included, as were intervention studies that assessed the effects of statin therapy compared with a placebo or no treatment and collected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes. Studies that compared statins with another statin or lipid-lowering agent were excluded. Study specific relative risks (RRs) were aggregated using random-effects models and were grouped by study-level characteristics. The review has been registered with PROSPERO, number CRD42016035622. FINDINGS: 36 eligible studies (13 cohort studies comprising 3 148 259 participants and 23 RCTs of statins vs placebo or no treatment comprising 118 464 participants) were included. In observational studies, the pooled RR for venous thromboembolism was 0·75 (95% CI 0·65-0·87; p<0·0001) when statin use was compared with no statin use. This association remained consistent when grouped by various study-level characteristics. In RCTs, the RR for venous thromboembolism was 0·85 (0·73-0·99; p=0·038) when statin therapy was compared with placebo or no treatment. Subgroup analyses suggested significant differences in the effect of statins by type of statin, with rosuvastatin having the lowest risk on venous thromboembolism compared with other statins 0·57 (0·42-0·75; p=0·015). There was no evidence of an effect of statin use on pulmonary embolism. Statin use was associated with a significant reduction in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0·77, 95% CI 0·69-0·86; p<0·0001). INTERPRETATION: Available evidence from observational and intervention studies suggest a beneficial effect of statin use on venous thromboembolism. In intervention studies, therapy with rosuvastatin significantly reduced venous thromboembolism compared with other statins. Further evidence is however needed to validate these findings. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kunutsor SK, Seidu S, Khunti K, et al. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. 2017. PMID: 28089655. doi:10.1016/S2352-3026(16)30184-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。